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DOI 10.1016/j.ccr.2012.03.048SUMMARYGermline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which includes
aberrant mucocutaneous pigmentation, and somatic LKB1mutations occur in 10% of cutaneous melanoma.
By somatically inactivating Lkb1 with K-Ras activation (±p53 loss) in murine melanocytes, we observed var-
iably pigmented and highly metastatic melanoma with 100% penetrance. LKB1 deficiency resulted in
increased phosphorylation of the SRC family kinase (SFK) YES, increased expression of WNT target
genes, and expansion of a CD24+ cell population, which showed increased metastatic behavior in vitro
and in vivo relative to isogenic CD24 cells. These results suggest that LKB1 inactivation in the context of
RAS activation facilitates metastasis by inducing an SFK-dependent expansion of a prometastatic, CD24+
tumor subpopulation.INTRODUCTION
The LKB1 (or STK11) gene encodes a serine/threonine kinase
that phosphorylates and activates several targets, including
AMPK and the AMPK-related kinases (Alessi et al., 2006). LKB1
regulates cancer-relevant cell biologic phenotypes, including
migration, invasion, metabolism, and polarity (Alessi et al.,
2006; Shah et al., 2008). Germline mutations in LKB1 cause the
Peutz-Jeghers syndrome (PJS; OMIM 175200), an autosomal,Significance
Although LKB1 loss has been linked to metastasis in epithelia
noma, the role of LKB1 inactivation in melanoma progression
Lkb1 loss and K-Ras activation develop highly penetrant mela
tion revealed that LKB1 loss leads to expansion of a highly inv
ing high levels of CD24, a modulator of metastasis and mar
subpopulation in response to LKB1 inactivation requires the
a mechanism whereby LKB1 regulates metastasis and ident
melanoma.dominant disorder characterized by hamartomatous polyps of
the gastrointestinal tract and increased mucocutaneous
pigmentation (Jeghers et al., 1949). Patients with PJS are tumor
prone, demonstrating a significantly increased risk for several
cancers (e.g., of colon, pancreas, breast, ovary, and testis)
(Giardiello et al., 2000; Lim et al., 2004; Sanchez-Cespedes,
2007). Somatic LKB1 mutations also are common in sporadic
cancers: most notably lung adenocarcinoma (30%; Ji et al.,
2007; Weir et al., 2007), cervical carcinoma (15%; Forbesl cancers, and LKB1 compromise occurs frequently in mela-
and metastasis is unknown. Here, we show that mice with
nomas that are extraordinarily metastatic. Further investiga-
asive and tumor-clonogenic subpopulation of cells express-
ker of stem-progenitor cells. The expansion of the CD24+
activity of the YES SRC family kinase. These data suggest
ify a promising therapeutic target, YES, in LKB1-deficient
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LKB1 Loss Promotes Melanoma Metastasiset al., 2011; Wingo et al., 2009), and melanoma (10%; Forbes
et al., 2011; Guldberg et al., 1999; Rowan et al., 1999).
In addition to the finding of frequent somatic inactivation in
melanoma, several lines of evidence suggest that LKB1 plays
an important role in melanocyte biology and limits melanocyte
transformation. Patients with PJS demonstrate hyperpigmenta-
tion of the lips, oral mucosa, hands, and feet, which are
comprised of atypical epidermal melanocytes. Although patho-
gnomonic for PJS, the pathologic basis for thesemacular lesions
is unknown. Moreover, recent reports have suggested that LKB1
is functionally inactivated by activating mutations of B-RAF
(Esteve-Puig et al., 2009; Zheng et al., 2009), which are found
in approximately 50% of human melanoma, suggesting that
functional compromise of LKB1 is common in melanoma.
A role for LKB1 in regulating tumor differentiation and metas-
tasis has been suggested in epithelial cancers. For example
somatic inactivation of Lkb1 combined with activation of K-Ras
in genetically engineered murine models (GEMMs) of lung
cancer results in tumors with an expanded spectrum of differen-
tiation and considerably augmented metastasis compared to
K-Ras-driven tumors lacking p53 or Ink4a/Arf (Ji et al., 2007).
LKB1 mutation is associated with advanced stage and metas-
tasis in human patients with aerodigestive carcinomas (Guervos
et al., 2007; Matsumoto et al., 2007). Loss of LKB1 has been
reported to promote metastatic behaviors (e.g., resistance to
anoikis, increased invasiveness) in a variety of epithelial cell
types in vitro through diverse mechanisms including inhibition
of SIK1 (Cheng et al., 2009) or AMPK (Taliaferro-Smith et al.,
2009) as well as activation of EMT, focal adhesion, and SRC
family kinases (SFKs) (Carretero et al., 2010). Given these obser-
vations suggesting a role for LKB1 in melanocyte biology and
transformation, we sought to determine the effects of LKB1 inac-
tivation in human cell lines and GEMMs of melanoma.
RESULTS
Lkb1 Deletion in Melanocytes In Vitro and In Vivo
We intercrossed an established 4-hydroxytamoxifen (4-OHT)-
inducible melanocyte-specific CRE allele (Tyr-CRE-ERT2, abbre-
viated ‘‘T’’; Bosenberg et al., 2006) and three conditional alleles:
Lox-Stop-Lox-(LSL)-KrasG12D (abbreviated ‘‘K’’; Johnson et al.,
2001); Lkb1L/L (Bardeesy et al., 2002); and p53L/L (Jonkers
et al., 2001). To investigate the effect of Lkb1 on melanocyte
growth and proliferation, we isolated murine melanocytes from
neonatal mice of these defined genotypes. Melanocytic origin
of the cells was confirmed by immunofluorescence staining for
the expression of tyrosinase and tyrosinase-related protein 1
(see Figure S1A available online). Cells were treated with
4-OHT in vitro to allow CRE activation and induce allelic
recombination, which was confirmed by PCR (data not shown).
Although wild-type (WT), TK, TLkb1L/L, and 4-OHT-untreated
control melanocytes grew poorly in vitro, 4-OHT-treated,
primary melanocytes from TKLkb1L/L and TKp53L/L; Lkb1L/L
mice demonstrated robust in vitro proliferation without growth
arrest over 2 months (Figure 1A; data not shown). Given that
Ink4a/Arf-deficient melanocytes are immortal in culture (Svider-
skaya et al., 2002), we assessed Ink4a/Arf expression in cultured
melanocytes with and without Lkb1. In accord with prior studies
by Bardeesy et al. (2002) and Ji et al. (2007), Ink4a/Arf expression752 Cancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc.was significantly attenuated in TKLkb1L/L versus TKmelanocytes
(Figure S1B). These findings suggest that Lkb1 loss leads to
melanocyte immortalization by compromising Ras-mediated
Ink4a/Arf activation.
To examine the role of Lkb1 in melanocytes in vivo, neonatal
mice were topically treated with 4-OHT to activate CRE and
induce recombination as previously described by Bosenberg
et al. (2006) and Monahan et al. (2010). Within 4 weeks of
4-OHT treatment, mice from K-Ras-expressing cohorts (TK,
TKLkb1L/L, TKp53L/L, and TKp53L/L; Lkb1L/L) developed melano-
cytic hyperproliferation and exhibited pigmented cutaneous
macules not seen in WT or 4-OHT-untreated littermates (Fig-
ure 1B; data not shown). These effects were stronger in
TKLkb1L/L and TKp53L/L cohorts than in the TK cohort, and the
most pronounced effects were observed in TKp53L/L; Lkb1L/L
mice. Accompanying the obviousmelanocytic hyperproliferation
in the tails and paws, coat color was more heterogeneous and
darker when K-Ras activation was combinedwith Lkb1 loss (Fig-
ure 1C; data not shown). Interestingly, the skin and coat color
from K-RasWT cohorts (TLkb1L/L, Tp53L/L, and Tp53L/L; Lkb1L/L)
appeared normal (Figure 1B). In aggregate these in vitro and
in vivo data show that homozygous Lkb1 inactivation is not suffi-
cient to induce melanocytic hyperproliferation in isolation but
potently cooperates with somatic K-Ras activation in this regard.
Lkb1 Loss Promotes Melanoma Formation
and Metastasis
We next followed these cohorts for melanoma formation. In
accord with our prior results, tumors were not observed in TK
mice, or in animals of any genotype without K-Ras activation
(TLkb1L/L, Tp53L/L, or Tp53L/L; Lkb1L/L) when followed to
70 weeks (Figure 2A). Combined somatic Lkb1 loss and K-Ras
activation, however, led to melanoma formation with 100%
penetrance and latencies ranging from 24 to 56 weeks (median
of 38.5). As previously reported by Monahan et al. (2010),
concomitant somatic p53 deletion combined with K-Ras activa-
tion also potently facilitated tumorigenesis, with a penetrance
and latency similar to that seen in the TKLkb1L/L mice. Despite
suggestions that Lkb1 loss compromises p53 function (Jones
et al., 2005; Karuman et al., 2001), we nonetheless noted strong
cooperation between deletion of Lkb1 and p53 in the context of
K-Ras activation (TKp53L/L; Lkb1L/L), with a sharp reduction of
median tumor latency to 11 weeks. Therefore, Lkb1 and p53
independently restrain Ras-mediated melanomagenesis.
Although metastasis is seen with multicopy N-Ras and c-Met
transgenic alleles (Ackermann et al., 2005; Scott et al., 2011),
metastasis is not a feature ofmelanomamodels driven by amulti-
copyH-Ras transgenic allele (Chin et al., 1997; Scott et al., 2011)
or endogenous expression of mutant K-Ras (Monahan et al.,
2010). Likewise, we have not observed hematogenous or lymph
node metastases in K-Ras-driven melanoma models with intact
Lkb1 function, including TKp16L/L, TKp53L/L, and TKp53L/L;
p16L/L mice (Table S1; see also Monahan et al., 2010). Against
this prior experience, we were surprised to note high-volume
metastasis in 100% of tumor-bearing mice with somatic K-Ras
activation and Lkb1 loss (TKLkb1L/L and TKp53L/L; Lkb1L/L). In
these mice, metastases were found in lymph node, lung, liver,
and spleen, but not in kidney or brain (Figures 2B and 2C; Table
S1). Because we do not observe metastasis in Lkb1-intact
Figure 1. Lkb1 Restrains Melanocytic Hyperprolif-
eration Induced by K-Ras Activation
(A) Growth curves of primary melanocyte cultures from
mice of indicated genotypes are illustrated. Cells were
treated with or without 4-OHT at 20 days postisolation to
activate CRE recombinase, and cell numbers were
counted during serial passage. At least three primary lines
were generated for each group, and representative results
are shown. Error bars show SD.
(B) Changes in pigmentation of representative 8-week-old
adult mice of the indicated melanocyte-specific geno-
types are shown. Mice without K-Ras activation exhibit
normal pigmentation, whereas K-Ras-expressing cohorts
showed pigmented macules on the paws and tails, with
increasing hyperpigmentation noted with concomitant
Lkb1 and/or p53 loss.
(C) Representative mice with melanocyte-specific loss of
Lkb1 and K-Ras activation show increased and hetero-
geneous coat color pigmentation compared to Lkb1-
intact mice.
See also Figure S1.
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Ink4a/Arf or p53 loss), we concluded that the strong enhance-
ment of metastasis in this model resulted from Lkb1 inactivation.
Although the primary melanomas in both TKLkb1L/L and
TKp53L/L; Lkb1L/L mice were unpigmented or hypopigmented,
metastases found in lymph node, lung, liver, and spleen con-
tained both unpigmented and deeply pigmented lesions (Figures
2B and 2C). These results are reminiscent of prior findings in lung
cancer by Ji et al. (2007), where Lkb1 loss both promotedmetas-
tasis as well as an extended spectrum of tumor differentiation
(e.g., adenocarcinoma versus squamous carcinoma). Therefore,
loss of Lkb1 appears to promote melanoma metastasis in the
context of increased differentiation potential, consistent with
an effect of Lkb1 on a tumor-initiating compartment with
augmented multipotency.
The YES SRC Family Kinase Is Activated by LKB1 Loss
and Results in Enhanced Metastatic Properties
In order to understand the mechanism whereby Lkb1 regulates
metastasis, we studied the effects of Lkb1 on cell migrationCancer Cell 21,and invasion in vitro. Toward that end, we
generated tumor cell lines from mice of defined
genotypes with and without Lkb1. We observed
a strong effect of Lkb1 loss on the in vitro wound
healing or scratch assay. Compared to mela-
noma cells with WT Lkb1, including TKp53L/L;
p16L/L and Tyr-Ras; Ink4a/Arf/ (‘‘TRIA’’; Chin
et al., 1997) cells, Lkb1-deficient melanoma
cells migrated more rapidly to fill an in vitro
wound (Figure 3A; Movies S1 and S2). Likewise,
loss of Lkb1 increased tumor invasiveness as
quantified using the Matrigel invasion assay
(Figure 3B), whereas proliferation in 2D culture
or soft agar was not influenced by Lkb1 status
(Figure S3). To confirm that these effects re-
flected Lkb1 function, Lkb1 null melanoma cells
were transduced with WT Lkb1 or kinase-deadLkb1 (Lkb1-KD), and Lkb1 expression was knocked down in
Lkb1 intact melanoma cell lines by transducing a small hairpin
RNA (shRNA) targeting Lkb1 (Figure 3C). In scratch assays and
Matrigel invasion, Lkb1 restoration in Lkb1 null tumor cells
inhibited cell migration and invasion, which was dependent
on the kinase activity of Lkb1. Likewise, partial knockdown of
Lkb1 in TKp53L/L; p16L/L cell lines significantly promoted cell
migration and invasion (Figures 3D and 3E). These data demon-
strate that loss of Lkb1 promotes melanoma cell migration and
invasion in vitro.
Unbiased proteomic analysis has revealed that Lkb1 loss acti-
vates SFKs in lung tumors (Carretero et al., 2010), and therefore,
we examined the effect of Lkb1 function on SFK phosphoryla-
tion, which correlates with SFK activation, in melanoma cells.
Lkb1 knockdown led to increased phosphorylation of SFKs
in murine TKp53L/L; p16L/L melanoma cells using a pan-SFK
phospho-specific antibody (Figure 4A). We further examined
the phosphorylation states of individual SFK members that
are abundantly expressed in melanoma, including Src, Fyn,
and Yes, by immunoprecipitation of each protein with an751–764, June 12, 2012 ª2012 Elsevier Inc. 753
Figure 2. Lkb1 Inactivation Promotes Melanoma Formation and Metastasis
(A) Kaplan-Meier analysis of melanoma-free survival of cohorts of indicated genotypes is presented.
(B and C) Representative primary tumors and metastases exhibiting variable pigmentation from TKLkb1L/L (B) and TKp53L/L; Lkb1L/L (C) mice are shown. L.N.,
lymph node. Arrow in (B) indicates a hypopigmented lung metastasis.
See also Table S1 and Figure S2.
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body to a shared phospho-tyrosine site (Y416). Although Src and
Fyn phosphorylation was not significantly changed by Lkb1
knockdown, Yes phosphorylation was significantly increased
by Lkb1 knockdown (Figure 4A). These results suggest that
Yes activity, at least in part, reflects Lkb1 function in melanoma.
To test whether increased SFK activity is involved in the effect
of Lkb1 loss on melanoma cells, we treated the TKp53L/L; p16L/L
melanoma cells with or without Lkb1 knockdown with the pan-
SFK inhibitor dasatinib. Dasatinib treatment inhibited melanoma
cell proliferation (Figure S4A); however, this effect was indepen-
dent of Lkb1 knockdown. In contrast whereas treatment with
dasatinib resulted in a modest decrease (14%) in cell migration
in Lkb1-intact cells, the effect was enhanced (27%) in melanoma
cells with Lkb1 knockdown (Figure 4B). A similar Lkb1-depen-
dent effect of dasatinib on cell invasion was noted in Matrigel
invasion (Figure 4C). These observations suggest that the activa-
tion of SFKs due to Lkb1 loss contributes to melanoma cell
migration and invasion, but not proliferation.
To confirm the effects of LKB1 loss and SFK activity across
species, we turned to the study of human melanoma cell lines.
We examined LKB1 expression in a panel of human melanoma
cell lines by western analysis and immunohistochemistry on
a cell line tissue microarray (TMA). LKB1 expression was hetero-754 Cancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc.geneous in these human melanoma cell lines, with an 30-fold
range of expression observed (Figures 4D and S4B). Two lines
with heterozygous LKB1 mutations (A2058 and PMWK) demon-
strated lowest expression of functional protein. No correlation
between LKB1 expression and RAS/RAF status was observed
(Figures 4D and S4B). Further examination revealed that phos-
pho-YES level anticorrelated with LKB1 expression in these
human melanoma cell lines (Figures 4E and 4F). To investigate
cell motility, invasion, and dasatinib sensitivity in these cells,
we focused on lines SKMel23, SKMel63, and A2058 with high,
medium, and low LKB1 expression, respectively. As shown
in Figures 4G and 4H, LKB1 expression anticorrelated with
cell motility, invasion, and sensitivity to dasatinib treatment. In
accord with prior studies showing a potent effect of Lkb1
haploinsufficiency on tumorigenesis (Ji et al., 2007), these data
show that complete loss of LKB1 is not required to promote
malignant growth because even reduced levels of functional
LKB1 protein promote phospho-YES expression and invasive
behavior in vitro.
To study the relationship of LKB1 and SFK activity in isogenic
lines, we knocked down LKB1 expression in A2058 cells (Fig-
ure S5A) and analyzed the phosphorylation status of all SFKs
using an 8-plex Luminex assay. In accord with the murine results
(Figure 4A), LKB1 knockdown in human A2058 cells resulted in
Figure 3. Loss of Lkb1 Promotes Melanoma Cell Migration and Invasion In Vitro
(A) Cells of indicated genotypes were subjected to in vitro wound healing or scratch assay. Representative photomicrographs of TKLkb1L/L cells and TKp53L/L;
p16L/L are shown on the left. Mean closure index, determined as described in the Supplemental Experimental Procedures, is graphed by genotype on the right
(n = 3 replicates per genotype).
(B) Cells of indicated genotypes were subjected to Matrigel invasion assay. Representative photomicrographs of cells that have invaded through Matrigel are
shown on the left and mean values graphed for cells of indicated genotypes on the right (n = 3 replicates per genotype).
(C) Western analysis of TKp53L/L; Lkb1L/L cells transduced with nonfunctional Lkb1-KD (‘‘kinase dead’’) or Lkb1, and TKp53L/L; p16L/L cells transduced with
nonspecific shRNA (NS) or shRNA targeting Lkb1 (shLkb1) is presented. U, untreated.
(D and E) Isogenic cells with and without Lkb1 as indicated were subjected to in vitro scratch assay (D) and Matrigel invasion assay (E) as in (A) and (B),
respectively. Error bars show SD. *p < 0.05; **p < 0.01.
See also Movies S1 and S2, and Figure S3.
Cancer Cell
LKB1 Loss Promotes Melanoma Metastasisan increase in YES phosphorylation as well as a more modest
but significant effect on FYN phosphorylation (Figure 5A). The
activity of all the other SFK members was not changed by
LKB1 knockdown (Figure 5A). To assess the role of individual
SFKs in mediating the effects of LKB1 loss, we knocked down
the expression of individual SFK members by transfecting
A2058 cells with siRNAs specifically targeting SRC, FYN, or
YES (Figure 5B). We noted that LKB1 knockdown in A2058 cells
had a similar effect on wound healing and Matrigel invasion to
that seen in murine melanoma (Figures 5C and 5D). This effect
of LKB1 inactivation was reverted by knockdown of YES, but
not FYN or SRC (Figures 5C and 5D). Of note the proliferation
of these cells was not affected by knockdown of YES (Fig-
ure S5B). The effect of LKB1 inactivation on YES phosphoryla-
tion, cell motility, and invasion was also observed in a second
humanmelanoma cell line, SKMel28, with relatively high expres-
sion of LKB1 (Figures S5C–S5F). Therefore, as opposed to lung
cancer where greater effect of LKB1 loss is on SRC (Carretero
et al., 2010), the effects of increased SFK activity on cell migra-tion and invasion associated with LKB1 loss in melanoma cells
are predominantly mediated by YES.
To determine the role of Yes activity in metastasis of Lkb1-
deficient melanoma in vivo, we employed the tail vein metastasis
assay. Targeting of Yes by shRNA was used to knock down
expression in TKp53L/L; Lkb1L/L melanoma cells (Figure S5G),
which did not affect cellular proliferation (Figure S5H). Cells
with or without Yes knockdown were injected into nude mice
via the tail vein, and lung metastases were examined 3 weeks
later. As shown in Figures 5E and 5F, TKp53L/L; Lkb1L/L mela-
noma cells were highly metastatic in vivo, whereas knockdown
of Yes resulted in a 7-fold decrease of tumor metastasis. In
contrast, dasatinib treatment (50 mg/kg/day orally) did not
significantly inhibit tumor metastasis in vivo (Figures S5I and
S5J). This result is in contrast to the in vitro effects of dasatinib
treatment (Figures 4B and 4C) as well as previous studies in
lung cancermodels by Carretero et al. (2010). Given this discrep-
ancy, we investigated the potency of dasatinib in cell-based
assays against SFKs. In accord with previous in vitro kinaseCancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc. 755
Figure 4. Lkb1 Loss Results in SFK Activation
(A) Representative western analysis of TKp53L/L; p16L/L cells with or without Lkb1 knockdown is shown. Cell lysates were either directly immunoblotted (IB) with
antibody against p-SFKs (Y416) or immunoprecipitated (IP) first with indicated antibodies against Src, Fyn, or Yes. NS, nonspecific shRNA.
(B) TKp53L/L; p16L/L melanoma cells with or without LKB1 knockdown were grown in media containing vehicle (DMSO) or dasatinib (30 nM). Closure index was
measured 12 hr after wounding.
(C) TKp53L/L; p16L/L melanoma cells with or without LKB1 knockdown were subjected to Matrigel invasion assay with and without treatment with pan-SFK
inhibitor, dasatinib (30 nM).
(D) Representative western analysis of indicated human melanoma cells with LKB1 quantification by LICOR analysis is shown.
(E) YES phosphorylation in indicated human melanoma cells with phospho-YES level quantification by LICOR analysis is presented. Cells were labeled with the
same number as in (D).
(F) Correlation analysis of LKB1 and phospho-YES expression in human melanoma cells is illustrated. Cells were labeled with the same number as in (D).
(G and H) SKMel23, SKMel63, and A2058 cells were treated with DMSO or 30 nM dasatinib and subjected to in vitro scratch assay (G) or Matrigel invasion
assay (H).
Error bars show SD. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S4.
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et al. (2009), Src and Fyn were inhibited by lower doses of dasa-
tinib than those needed to inhibit Yes (Figure S5K, 10-fold
difference in the EC50 for Src versus Yes). Therefore, whereas
dasatinib is adequately potent for in vitro studies (Figures 4B,
4C, 4G, and 4H), in vivo inhibition of Yes activity appears to
require greater doses of dasatinib than those needed to inhibit
SRC, the more important SFK in LKB1-deficient lung cancer.
These data suggest that an SFK inhibitor with greater potency756 Cancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc.against YES may exhibit better antimelanoma efficacy in
humans.
Microarray Analysis of Lkb1-Regulated Transcript
To provide a mechanistic understanding of how LKB1 loss
promotes melanomametastasis, we performed RNA expression
profiling on 20 melanoma cell lines and 9 primary tumors with or
without functional Lkb1. The transcriptional effects of Lkb1 inac-
tivation were large: a total of 2,767 and 15,795 genes were
Figure 5. The Effects of LKB1 Loss on Melanoma Cells Are Mediated by the YES Kinase
(A) Tyrosine phosphorylation status of SFKmembers in A2058 cells with or without LKB1 knockdown is illustrated. Mean values of three replicates per kinase are
graphed. MFI, median fluorescence intensity. NS, nonspecific shRNA.
(B) A2058 cells expressing shLKB1were transfectedwith scrambled control siRNAs or siRNAs targeting SRC, FYN, or YES. Cell lysates were immunoblotted with
indicated antibodies 48 hr after transfection. U, untreated.
(C and D) A2058 cells with or without LKB1 knockdown were transfected with indicated SFK siRNAs. Cells were subjected to in vitro scratch assay (C) or Matrigel
invasion assay (D) 48 hr after siRNA transfection.
(E and F) Luciferase-expressing TKp53L/L; Lkb1L/Lmelanoma cells with or without Yes knockdown were injected into nudemice via tail vein. Mice were examined
by luciferase imaging (E) and dissection (F). Luminescence was quantified (E).
Error bars show SD. **p < 0.01; ***p < 0.001.
See also Figure S5.
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LKB1 Loss Promotes Melanoma Metastasisdifferentially associated with Lkb1 competence in cell lines and
primary tumors, respectively (false discovery rate [FDR] <5%)
(Table S2). To better understand pathways regulated by Lkb1
in melanoma cells, we constructed an ‘‘overlap’’ list of tran-
scripts that were differentially regulated by Lkb1 inactivation in
both melanoma cell lines and primary tumors. Toward that
end, we picked the top 1,000 upregulated and downregulated
transcripts associated with Lkb1 loss in cell lines and primary
tumors and identified all transcripts appearing on both lists.
This winnowed overlap list contained 55 upregulated genes,
and 55 downregulated genes (Figures S6A and S6B). Gene Set
Enrichment Analysis (GSEA) of this overlap list indicated a
significant enrichment for several pathways (Table S3), with
targets of mir27 and Lef1 being particularly highly represented
(Figures S6A and S6B). Lef1 is a critical transcriptional activator
responsive to WNT/b-catenin, and this observation is consistent
with recent work suggesting that mir27 expression promotes
metastasis via activation of b-catenin signaling (Zhang et al.,
2011). Moreover, we noted amore than 2-fold increased expres-
sion of other validated WNT targets (Axin2, Nkd1, Lgr5, and
Bmp4, FDR <1%) in Lkb1-deficient tumors. Therefore, thesetranscriptional analyses suggest that increased expression of
targets of mir27 andWnt/b-catenin is associated with melanoma
metastasis.
LKB1 Inactivation Induces an SFK-Dependent
Expansion of a Prometastatic, CD24+ Tumor
Subpopulation
The association of Lkb1 loss with increased Lef1 expression has
been previously noted in lung cancer by Ji et al. (2007), and
therefore, we looked for other transcripts associated with Lkb1
loss in both tissues. Although we also noted increased expres-
sion of Nedd9 and Vegf-c in both tumor types (data not shown),
the most reliably upregulated gene associated with LKB1 loss in
cell lines and primary tumors from both tumor types was CD24
(‘‘CD24a’’ in the mouse, Figure S6A; Ji et al., 2007). We consid-
ered this protein of interest for further study given its role as
a known modulator of advanced disease and metastasis
(Baumann et al., 2005; Kristiansen et al., 2003; Lee et al., 2011;
Senner et al., 1999) and marker of stem-progenitor cells in
several tumor types (Al-Hajj et al., 2003; Gao et al., 2010; Lee
et al., 2011). Prior work has demonstrated heterogeneousCancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc. 757
Figure 6. Lkb1 Loss Expands a Prometastatic CD24+ Cell Population
(A) CD24 expression of melanoma cells of indicated genotypes was examined by flow cytometry.
(B) TKp53L/L; Lkb1L/L cells were transduced with Lkb1-KD or Lkb1. TKp53L/L; p16L/L cells were transduced with NS or shLkb1. Cells with and without Lkb1
function as indicated were examined for CD24 expression by flow cytometry.
(C and D) CD24+ cells and CD24 cells were isolated from TKp53L/L; Lkb1L/L cells by FACS. Sorted cells were subjected to scratch assay (C) andMatrigel invasion
assay (D).
(E) CD24+ and CD24 cells were isolated from TKp53L/L; Lkb1L/L and TKp53L/L; p16L/L cells. Cell lysates were subjected to direct immunoblotting or immuno-
blotting following immunoprecipitation as indicated.
Error bars show SD. **p < 0.01; ***p < 0.001.
See also Figure S6 and Tables S2 and S3.
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LKB1 Loss Promotes Melanoma Metastasisexpression of CD24 in human melanoma (Shields et al., 2007;
Stuelten et al., 2010), and expression is not uniform on all cells
within a given cell line. Instead, consistent with its ability to
mark tumor-initiating fractions, CD24 expression is noted on
a tumor subfraction, with expression ranging from <1% to
13% of cells in melanoma lines.
We therefore investigated the relationship of Lkb1 status and
CD24 expression. Cell lines derived from murine melanomas
with intact Lkb1 function exhibited a low fraction (<3%) of
CD24+ cells. Remarkably, inactivation of Lkb1 was associated
with a marked expansion of the CD24+ population ranging from
10% to more than 30% of cells (Figures 6A, 6B, S6C, and S6D).
Correspondingly, restored expression of Lkb1 in Lkb1 null
melanoma cells suppressed CD24 expression within 6 days of
transduction, which was dependent on the kinase activity of
Lkb1 (Figures 6B and S6E). Likewise, Lkb1 null (TKLkb1L/L)
tumors contained an increased CD24+ subpopulation compared758 Cancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc.to Lkb1-competent (TRIA) tumors in vivo (Figure S6F). These
data demonstrate a highly dynamic, 3- to 10-fold effect of
Lkb1-kinase activity on expression of cell surfaceCD24, a known
facilitator of metastasis.
Given that CD24 expression (both increased and decreased)
has been associated with functional heterogeneity and tumor-
initiating cells in other cancer types, we examined the in vitro
properties of CD24+ versus CD24 cells in melanoma cell lines.
CD24+ and CD24 cells were isolated from TKp53L/L; Lkb1L/L
cells by fluorescence-activated cell sorting (FACS) (Figure S6G),
and the separated populations were assessed for proliferation,
migration, and invasion. Although no difference was observed
in the proliferation of CD24+ versus CD24 cells (Figure S6H),
CD24+ cells showed significantly increased cell migration and
invasion (Figures 6C and 6D). Correspondingly, Yes phosphory-
lation was higher in CD24+ cells than in CD24 cells from both
Lkb1-competent and -deficient cell lines (Figure 6E). These
Figure 7. Expansion of the CD24+ Fraction in Response to LKB1 Inactivation Requires YES Kinase
(A) Percentage of CD24+ cells in indicated human melanoma cells determined by flow cytometry is illustrated.
(B) Correlation analysis of LKB1 and CD24 expression in human melanoma cells is presented. LKB1 expression was quantified in Figure 4D. Cells were labeled
with the same number as in (A) and Figure 4D.
(C) CD24 expression in A2058 human melanoma cells increases with LKB1 knockdown (shLKB1). U, untreated. NS, nonspecific shRNA.
(D and E) A2058 cells with LKB1 knockdown were treated with the indicated concentrations of dasatinib and harvested for analysis at the indicated times. The
expression of CD24 mRNA (D) was measured by quantitative RT-PCR and calculated as relative expression to A2058 cells with NS-shRNA. The expression of
CD24 protein (E) was measured by flow cytometry (n = 3 replicates).
(F) A2058 cells with LKB1 knockdownwere transfectedwith indicated SFK siRNAs. CD24 expressionwasmeasured by flow cytometry 72 hr after the transfection
(n = 3 replicates).
Error bars show SD. *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S7.
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LKB1 Loss Promotes Melanoma Metastasisresults suggest that CD24 expression is associated with
increased metastatic behavior in vitro as well as Yes phosphor-
ylation and that increased Yes activation is a common feature
of the CD24+ subpopulation regardless of Lkb1 status in
melanoma.
To confirm the effects of LKB1 loss on CD24 expression in
human cells, we examined CD24 expression in a large panel of
human melanoma cell lines. CD24 expression varied over a
28-fold range and anticorrelated with LKB1 expression (Figures
7A and 7B). In A2058 cells, shRNA targeting of LKB1 led to
a marked and rapid increase in CD24 expression (from 4% to
36% with LKB1 knockdown) (Figure 7C), and a similar effect
was also observed in SKMel28 cells (Figure S7A). Expression
of CD44, another commonly used ‘‘tumor stem cell’’ marker,
was not modulated by LKB1 knockdown within this time frame
(Figure S7B). As in murine cells, the activity of YES and total
SFKs was predominantly observed in CD24+ compared to
CD24 cells (Figures S7C and S7D). Moreover, the level of phos-
pho-ERKwas also increased by LKB1 knockdown,with a greatereffect in CD24+ versus CD24 cells, whereas no effect of LKB1
knockdown was noted on phospho-AKT levels (Figure S7E).
The increase in CD24 mRNA and protein expression due to
LKB1 loss was suppressed in a dose-dependent fashion by tran-
siently treating cells with dasatinib in both human and murine
melanoma cells (Figures 7D, 7E, and S7F), with CD24 mRNA
sharply decreasing with as little as 12 hr of dasatinib treatment.
In accordwith the in vitromotility and invasion results (Figures 5C
and 5D), the effect of LKB1 loss on CD24 expression was
rescued by siRNA to YES, but not SRC or FYN (Figure 7F). These
data show that the ability of LKB1 loss to induce expansion of the
prometastatic CD24+ compartment requires the activity of YES
kinase.
We next performed an analysis of the relationship between
CD24 expression and tumor formation. More colony-forming
cells (CFCs) were noted in the CD24+ fraction from both Lkb1-
deficient (TKp53L/L; Lkb1L/L) and Lkb1-competent (TKp53L/L;
p16L/L) cell lines (Figure S8A). We investigated the in vivo tumor
growth of isolated CD24+ and CD24 cells (Figure S8B) byCancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc. 759
Figure 8. CD24+ Cells Exhibit Higher Metastatic Potential than CD24– Cells In Vivo
(A–F) CD24+ and CD24 cells were isolated from luciferase-expressing Lkb1-deficient (TKp53L/L; Lkb1L/L, A–C) and Lkb1-competent (TKp53L/L; p16L/L, D–F)
melanoma cells and injected into nudemice via tail vein (n = 6mice for each group). Threeweeks after tail vein injection, micewere examined by luciferase imaging
(A and D) and dissection (B and E). Luminescence was quantified, and statistical analysis was performed. Error bars showSD. **p < 0.01; ***p < 0.001. Tumor cells
were examined by flow cytometry for CD24 expression (C and F) prior to tail vein injection (parental) or 3 weeks later after metastatic growth in the lung
(metastasis). No metastasis sample was retrievable from the CD24 fraction of TKp53L/L; p16L/L cells. See also Figure S8.
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LKB1 Loss Promotes Melanoma Metastasisxenograft transplantation. Although all mice developed tumors,
CD24+ cells grew more rapidly whether they were derived from
Lkb1-defective or -competent melanomas (Figure S8C). FACS-
sorted CD24+ and CD24 cells were injected into nude mice
via tail vein, with in vivo metastases examined 3 weeks later.
CD24+ cells from both Lkb1-deficient and Lkb1-competent
melanomas exhibited greater metastatic ability than CD24 cells
(Figure 8). Examination of CD24 expression detected both
CD24+ and CD24 cells in tumor metastases formed by either
CD24+ or CD24 cells (Figures 8C and 8F). Yes knockdown
significantly attenuated the size of the CD24+ subpopulation in
metastases formed after tail vein injection of TKp53L/L; Lkb1L/L
(Figure S8D). These data indicate that CD24+ melanoma cells
exhibit a qualitative increase in metastatic propensity regardless
of Lkb1 status and suggest that Lkb1 inactivation predominantly
promotes tumor progression by leading to a marked expansion
of this CD24+ fraction.
DISCUSSION
In this work we show that mice with melanocyte-specific Lkb1
loss andK-Ras activation develop highly metastatic melanomas.
Lkb1-deficient melanoma cells increased invasive behavior760 Cancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc.in vitro compared to isogenic Lkb1-competent melanoma cells.
Further investigation revealed that LKB1 deficiency resulted in
activation of SFKs, particularly YES, and expansion of a CD24+
cell population that showed increased invasive behavior in vitro
and in vivo. Inhibition of YES activity suppressed CD24 expres-
sion and decreased metastatic behavior. Collectively, these
results demonstrate that LKB1 functions as a strong suppressor
of melanomametastasis by regulating YES activity, which deter-
mines the size of a prometastatic CD24+ tumor subpopulation.
Of interest with regard to the phenotypic expression of PJS,
we showed that combined melanocyte-specific Lkb1 loss and
K-Ras activation results in increased melanocyte proliferation
and in vivo hyperpigmentation. The excess melanocytic prolifer-
ation in TKLkb1L/L (and TKLkb1L/+), but not in TLkb1L/L, mice,
suggests that melanocytic hyperproliferation seen in patients
with PJS may reflect sporadic secondary events that activate
regulators of proliferation (e.g., RAS) rather than loss of the
second copy of LKB1. Therefore, TKLkb1L/L mice serve as
a model to study this poorly understood feature of PJS. A weak-
ness of this model is the reliance on K-RAS mutation, which
is 10-fold less common than that of N-RAS in human mela-
noma. To date, we have not been able to generate tumors with
an N-RasLSL allele featuring a codon 12 mutation (Haigis et al.,
Cancer Cell
LKB1 Loss Promotes Melanoma Metastasis2008), even when combined with inactivation of several different
tumor suppressor genes. The explanation for this difference in
the melanoma-promoting effects of the various RAS isoforms
is an area of active ongoing investigation.
In addition to altered pigmentation, TKLkb1L/L and TKp53L/L;
Lkb1L/L mice exhibited highly metastatic melanoma. Although
metastasis has been reported in a small number of autochtho-
nous murine tumor models (Ackermann et al., 2005; Guy et al.,
1992; Scott et al., 2011), these models feature lower volumes
of metastatic disease with variable penetrance and rely on
supraphysiologic expression of oncogenes. In contrast the
present model couples melanocyte-specific, somatic single-
copy K-Ras activation under the control of its endogenous
promoter with homozygous Lkb1 deletion to produce 100%
penetrance of metastasis with a high burden of metastatic
disease. For example several tumor-bearing TKLkb1L/L and
TKp53L/L; Lkb1L/L mice exhibited >50% involvement of the liver,
lung, and/or spleen with multifocal metastasis (Figures 2B, 2C,
and S2). We believe that the high burden and penetrance of
metastases in this model address a significant unmet need in
cancer research for experimentally tractable, highly metastatic,
autochthonous tumor models. Moreover, in murine models of
both lung cancer (Carretero et al., 2010; Ji et al., 2007) and
melanoma, Lkb1-deficient tumors demonstrate increased histo-
morphometric heterogeneity and more frequent metastasis
compared to tumors lacking p53 or Ink4a/Arf. Because metas-
tasis is not noted in TKp53L/L, TKp16L/L, or TRIA mice (Table
S1; Monahan et al., 2010), the effects of Lkb1 loss on metastasis
are not explained by the effects of Lkb1 on expression of
p16INK4a, Arf, or p53.
Of interest, Dankort et al. have recently reported melanoma
metastasis, albeit with lower tumor burdens, in 4-OHT-treated
Tyr-CRE-ERT2B-RafLSL/+PtenL/L mice (Dankort et al., 2009).
This result is consistent with the notion that B-Raf mutation
(Esteve-Puig et al., 2009; Zheng et al., 2009) induces a partial
compromise of Lkb1 function. More recently, this group has
shown that WNT/b-catenin activation strongly enhances metas-
tasis in this model (Damsky et al., 2011), which matches our
findings of increased expression of b-catenin/Lef1 targets in
Lkb1-deficient tumors (Figures S6A and S6B). It is not clear
from our data if the YES-dependent expansion of the prometa-
static, CD24+ melanoma subfraction requires expression of
b-catenin/LEF1 targets, but both events appear to result from
LKB1 inactivation.
SFK activity has been shown to closely associate with mela-
noma metastasis (Homsi et al., 2009; Putnam et al., 2009), and
prior work in particular has suggested a prominent role for YES
among the SFKs in melanoma pathogenesis. For example the
kinase activity of YES, but not SRC, is significantly higher in
most melanoma cell lines than in melanocytes (Loganzo et al.,
1993). Likewise, activation of YES, but not FYN or SRC, appears
essential to mediate the increased invasiveness of human
melanoma cells in response to stimulation with gangliosides or
neurotrophins (Hamamura et al., 2011; Marchetti et al., 1998).
Although the mechanism whereby loss of LKB1 kinase activity
induces YES activation is not clear, the present data suggest
YES as a promising therapeutic target in melanoma lacking
LKB1 function. Dasatinib exhibits modest antimelanoma activity
in human patients (Kluger et al., 2011). Because we and others(Deguchi et al., 2008; Konecny et al., 2009) have noted an
10-fold decrease in the potency of dasatinib for YES compared
to SRC and other SFKs, these results suggest that an SFK inhib-
itor with greater potency against YES inhibitor would exhibit
greater in vivo antimelanoma efficacy.
Increased YES activity in turn leads to an expansion of a tumor
subpopulation that is characterized by increased cell motility and
invasion, as well as CD24+ expression. Surprisingly, although
LKB1 function is inhibited in most or all of the cells, the activation
of YES and expression of CD24 in response to LKB1 inactivation
is limited to a minority (10%–30%) of cells, which exhibit
enhanced metastatic properties. A CD24+ population of cells is
present, albeit at lower frequency, in LKB1-competent mela-
noma cells, and loss of LKB1 kinase activity appears to induce
an expansion of this prometastatic fraction. The prometastatic
properties of CD24+ cells were increased relative to isogenic
CD24 cells regardless of whether the CD24+ cells were derived
from LKB1-deficient or -competent cell lines. This observation is
consistent with evidence that CD24 expression is associated
with advanced disease and increased metastasis in glioma
and epithelial cancers (Baumann et al., 2005; Kristiansen et al.,
2003; Lee et al., 2011; Senner et al., 1999). Therefore, our data
are most consistent with the model that the principal effect of
LKB1 inactivation with regard to metastasis is to markedly
increase the frequency of this prometastatic subpopulation.
Importantly, whereas CD24 expression appears to play
a direct role in facilitating tumor metastasis, it has also been
observed to mark heterogeneous subpopulations (e.g., ‘‘tumor
stem cells’’) of a variety of cancers (Al-Hajj et al., 2003; Gao
et al., 2010; Lee et al., 2011). Therefore, our data are consistent
with the model that CD24 expression directly facilitates mela-
noma metastasis but also that CD24 expression merely serves
as a marker of a tumor subpopulation with increased metastatic
properties. With regard to the latter possibility, LKB1 loss led to
an increase in a tumor subfraction with increased colony-forming
activity and expanded tumor differentiation potential in vivo (as
reflected by the variable degree of tumor pigmentation), which
are properties of ‘‘tumor stem cells.’’ Although the concept of
a tumor stem cell in melanoma is controversial, our results are
compatible with the possibility that the increased tumor hetero-
geneity noted in the setting of LKB1 inactivation reflects an
augmented tumor stem cell fraction.
In summary this work shows a prominent role for LKB1
in melanocyte biology and the suppression of melanoma
metastasis. We observed that a principal effect of LKB1 loss
on metastasis required expansion of a CD24+ prometastatic
tumor subfraction that exhibited some properties of a tumor
stem cell. Expansion of this compartment required the activity
of YES kinase. These data suggest that a determination of
LKB1 mutational status in patients with advanced melanoma
will contribute to prognosis prediction and identify promising
therapeutic targets (YES and CD24) in melanoma with compro-
mised LKB1 function.EXPERIMENTAL PROCEDURES
Mouse Colony
Mice were housed and treated in accordance with protocols approved by the
institutional care and use committee for animal research at the University ofCancer Cell 21, 751–764, June 12, 2012 ª2012 Elsevier Inc. 761
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LKB1 Loss Promotes Melanoma MetastasisNorth Carolina. Animals were generated and genotyped as previously
described: T (Bosenberg et al., 2006); K-RasL/L (or ‘‘K’’; Johnson et al., 2001);
Lkb1L/L (Bardeesy et al., 2002); p53L/L (Jonkers et al., 2001); and TRIA (Chin
et al., 1997). All cohorts reported in Figures 1 and 2 (TK, TLkb1L/L, Tp53L/L,
Tp53L/L; Lkb1L/L, TKLkb1L/L, TKp53L/L, TKp53L/L; Lkb1L/L) were newly gener-
ated and contemporaneously housed for this work. Data from the TKp16L/L
and TKp53L/L; p16L/L cohorts shown in Table S1 are a historical comparison
from a prior study by Monahan et al. (2010). All cohorts were N1 in C57BL/6
and, where possible, compared to littermate controls. To induceCRE recombi-
nase in vivo, pups were treated with 4-OHT as described by Dankort et al.
(2009) and Monahan et al. (2010). In tumor survival cohorts, mice were moni-
tored for tumors three times per week and sacrificed for tumor size (>1.3 cm)
or morbidity (ulceration, weight loss). All sacrificed animals were analyzed for
metastasis by necropsy. H&E of tumors after formalin fixation and paraffin
embedding was performed, with analysis showing spindle-shaped melanoma
with variable pigmentation (Figure S2). Melanocytic lineage was further con-
firmed by staining for melanocytic markers (Figure S2). Kaplan-Meier analysis
of melanoma-free survival was determined using GraphPad Prism software.
Cell Lines and Cell Culture
Primary melanocyte cultures and murine tumor cell lines were generated as
described by Bennett et al. (1989) and Sharpless et al. (2002). Human mela-
noma cells studied were immortalized cell lines and were IRB exempt. To
induce CRE recombinase in vitro, primary melanocyte cultures were treated
with 4-OHT at 20 days postisolation for 48 hr. Melanoma cells weremaintained
in DMEM containing 10% FBS. Dasatinib was from LC Laboratories (D-3307).
Immunoprecipitation, immunoblotting, immunofluorescence, SFK 8-Plex, and
quantitative RT-PCR assays are described in the Supplemental Experimental
Procedures.
Cell Migration and Invasion Assays
The in vitro scratch (wound healing) assay was performed as described previ-
ously by Carretero et al. (2010). Matrigel invasion was determined using
invasion chambers obtained from BD Biosciences, with assays performed
according to the manufacturer’s instructions. See Supplemental Experimental
Procedures.
Flow Cytometric Analysis and FACS
Cells were labeled with indicated antibodies, washed, resuspended, and
strained (40 mm). Data were recorded with a CyAn ADP flow cytometer
(Dako Cytomation) and analyzed by FlowJo software. Antibodies used were
Anti-Human APC-CD24 (eBioscience), Anti-Mouse FITC-CD24 (eBioscience),
Anti-Mouse PE-Cy5-CD24 (eBioscience), and Anti-Human FITC-CD44 (BD
Biosciences). For CFC assay, single cells were FACS-sorted into individual
wells of 96-well plates. CFCswere counted after culturing the cells for 3weeks.
Tail Vein Metastasis Assay
Five to 6-week-old female nu/nu mice were maintained under pathogen-free
conditions. Cells were transducedwith a luciferase reporter gene prior to injec-
tion. CD24+ cells and CD24 cells were separated by FACS. A total of 0.5 3
105 cells were injected into nu/nu mice via tail vein (n = 6 per experimental
group). Three weeks after the injection, mice were subjected to luciferase
imaging and necropsy to determine lung metastasis. Luminescence was
quantified using Living Image software (Caliper Life Sciences).
shRNA, siRNA, and Lentiviruses
shRNA constructs used for knocking down LKB1 expression in A2058 cells
were described previously by Carretero et al. (2010). shRNA targeting Yes
was from Thermo Scientific. For suppression of Src, Fyn, and Yes expression,
cells were transfected with the appropriate antisense oligonucleotides using
Lipofectamine RNAiMAX (Invitrogen). Src siRNA (sc-29228), Fyn siRNA
(sc-29321), Yes siRNA (sc-29860), and scrambled control siRNA (sc-37007)
were from Santa Cruz Biotechnology.
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